ArticleMolecules (Basel, Switzerland)2025
Flow Synthesis of Pharmaceutical Intermediate Catalyzed by Immobilized DERA: Comparison of Different Immobilization Techniques and Reactor Designs.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The enzymatic synthesis of statin intermediates offers a sustainable alternative to traditional multistep chemical methods. This study investigates the continuous flow synthesis of statin precursors in a millireactor using 2-deoxy-D-ribose-5-phosphate aldolase (DERA) immobilized on mesoporous silica foam (MCF) and magnetic nanoparticles (MNPs). Two types of flow millireactors, a fixed bed millireactor for MCF and a fluidized bed millireactor for MNP, were designed. Key performance indicators including conversion, selectivity, yield, and productivity were analyzed and compared with the batch reactor results. The MNP-based fluidized bed millisystem demonstrated superior conversion (97.78%) and yield (95.85%) under optimized conditions, outperforming both batch and MCF-based millisystems. This work highlights the importance of optimizing immobilization techniques and reactor configurations to enhance enzyme stability and catalytic efficiency in continuous biocatalytic processes, particularly for pharmaceutical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.